Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Newly identified LMO3-BORCS5 fusion oncogene in Ewing sarcoma at relapse is a driver of tumor progression.

Dupain C, Gracia C, Harttrampf AC, Rivière J, Geoerger B, Massaad-Massade L.

Oncogene. 2019 Sep 5. doi: 10.1038/s41388-019-0914-3. [Epub ahead of print]

PMID:
31488873
2.

A novel therapeutic approach to colorectal cancer in diabetes: role of metformin and rapamycin.

Geagea AG, Rizzo M, Jurjus A, Cappello F, Leone A, Tomasello G, Gracia C, Al Kattar S, Massaad-Massade L, Eid A.

Oncotarget. 2019 Feb 12;10(13):1284-1305. doi: 10.18632/oncotarget.26641. eCollection 2019 Feb 12.

3.

Discovery of New Fusion Transcripts in a Cohort of Pediatric Solid Cancers at Relapse and Relevance for Personalized Medicine.

Dupain C, Harttrampf AC, Boursin Y, Lebeurrier M, Rondof W, Robert-Siegwald G, Khoueiry P, Geoerger B, Massaad-Massade L.

Mol Ther. 2019 Jan 2;27(1):200-218. doi: 10.1016/j.ymthe.2018.10.022. Epub 2018 Nov 2.

PMID:
30509566
4.

New Formulation for the Delivery of Oligonucleotides Using "Clickable" siRNA-Polyisoprenoid-Conjugated Nanoparticles: Application to Cancers Harboring Fusion Oncogenes.

Massaad-Massade L, Boutary S, Caillaud M, Gracia C, Parola B, Gnaouiya SB, Stella B, Arpicco S, Buchy E, Desmaële D, Couvreur P, Urbinati G.

Bioconjug Chem. 2018 Jun 20;29(6):1961-1972. doi: 10.1021/acs.bioconjchem.8b00205. Epub 2018 May 11.

PMID:
29727181
5.

Tea catechins induce crosstalk between signaling pathways and stabilize mast cells in ulcerative colitis.

Gerges Geagea A, Rizzo M, Eid A, Hajj Hussein I, Zgheib Z, Zeenny MN, Jurjus R, Uzzo ML, Spatola GF, Bonaventura G, Leone A, Massaad-Massade L, Jurjus A.

J Biol Regul Homeost Agents. 2017 Oct-Dec;31(4):865-877.

PMID:
29254289
6.

Oral manifestations of inflammatory bowel disease.

Mortada I, Leone A, Gerges Geagea A, Mortada R, Matar C, Rizzo M, Hajj Hussein I, Massaad-Massade L, Jurjus A.

J Biol Regul Homeost Agents. 2017 Jul-Sep;31(3):817-821.

PMID:
28958141
7.

Effects of natural environment on reproductive histo-morphometric dynamics of female dromedary camel.

Ali HM, Qureshi AS, Hussain R, Urbinati G, Mustafa MZ, Ali F, Manan A, Massaad-Massade L.

Anim Reprod Sci. 2017 Jun;181:30-40. doi: 10.1016/j.anireprosci.2017.03.012. Epub 2017 Mar 29.

PMID:
28413155
8.

Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine.

Dupain C, Harttrampf AC, Urbinati G, Geoerger B, Massaad-Massade L.

Mol Ther Nucleic Acids. 2017 Mar 17;6:315-326. doi: 10.1016/j.omtn.2017.01.005. Epub 2017 Feb 9. Review.

9.

Induction of TTF-1 or PAX-8 expression on proliferation and tumorigenicity in thyroid carcinomas.

Dupain C, Ali HM, Mouhoub TA, Urbinati G, Massaad-Massade L.

Int J Oncol. 2016 Sep;49(3):1248-58. doi: 10.3892/ijo.2016.3617. Epub 2016 Jul 7.

PMID:
27573549
10.

Knocking Down TMPRSS2-ERG Fusion Oncogene by siRNA Could be an Alternative Treatment to Flutamide.

Urbinati G, de Waziers I, Slamiç M, Foussignière T, Ali HM, Desmaële D, Couvreur P, Massaad-Massade L.

Mol Ther Nucleic Acids. 2016 Mar 29;5:e301. doi: 10.1038/mtna.2016.16.

11.

Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer.

Urbinati G, Ali HM, Rousseau Q, Chapuis H, Desmaële D, Couvreur P, Massaad-Massade L.

PLoS One. 2015 May 1;10(5):e0125277. doi: 10.1371/journal.pone.0125277. eCollection 2015.

12.

Effects of siRNA on RET/PTC3 junction oncogene in papillary thyroid carcinoma: from molecular and cellular studies to preclinical investigations.

Ali HM, Urbinati G, Chapuis H, Desmaele D, Bertrand JR, Couvreur P, Massaad-Massade L.

PLoS One. 2014 Apr 23;9(4):e95964. doi: 10.1371/journal.pone.0095964. eCollection 2014.

13.

Effects of silencing the RET/PTC1 oncogene in papillary thyroid carcinoma by siRNA-squalene nanoparticles with and without fusogenic companion GALA-cholesterol.

Ali HM, Maksimenko A, Urbinati G, Chapuis H, Raouane M, Desmaële D, Yasuhiro H, Harashima H, Couvreur P, Massaad-Massade L.

Thyroid. 2014 Feb;24(2):327-38. doi: 10.1089/thy.2012.0544. Epub 2014 Jan 9.

PMID:
23885719
14.

Significance and applications of nanoparticles in siRNA delivery for cancer therapy.

Ali HM, Urbinati G, Raouane M, Massaad-Massade L.

Expert Rev Clin Pharmacol. 2012 Jul;5(4):403-12. doi: 10.1586/ecp.12.33. Review.

PMID:
22943120
15.

Lipid conjugated oligonucleotides: a useful strategy for delivery.

Raouane M, Desmaële D, Urbinati G, Massaad-Massade L, Couvreur P.

Bioconjug Chem. 2012 Jun 20;23(6):1091-104. doi: 10.1021/bc200422w. Epub 2012 Mar 15. Review.

PMID:
22372953
16.

Wnt/β-catenin signaling pathway is a direct enhancer of thyroid transcription factor-1 in human papillary thyroid carcinoma cells.

Gilbert-Sirieix M, Makoukji J, Kimura S, Talbot M, Caillou B, Massaad C, Massaad-Massade L.

PLoS One. 2011;6(7):e22280. doi: 10.1371/journal.pone.0022280. Epub 2011 Jul 21.

17.

Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma.

Raouane M, Desmaele D, Gilbert-Sirieix M, Gueutin C, Zouhiri F, Bourgaux C, Lepeltier E, Gref R, Ben Salah R, Clayman G, Massaad-Massade L, Couvreur P.

J Med Chem. 2011 Jun 23;54(12):4067-76. doi: 10.1021/jm2000272. Epub 2011 May 18.

PMID:
21561161
18.

[TTF-1: neither angel nor demon].

Gilbert-Sirieix M, Massaad-Massade L.

Med Sci (Paris). 2011 Feb;27(2):183-6. doi: 10.1051/medsci/2011272183. Epub 2011 Mar 8. Review. French.

19.

Effects of silencing RET/PTC1 junction oncogene in human papillary thyroid carcinoma cells.

Gilbert-Sirieix M, Ripoche H, Malvy C, Massaad-Massade L.

Thyroid. 2010 Oct;20(10):1053-65. doi: 10.1089/thy.2010.0006.

PMID:
20615140
20.

Down-regulation of C/EBPalpha in breast cancer cells by hypoxia-estrogen combination is mainly due to hypoxia.

Seifeddine R, Fulchignoni-Lataud MC, Massaad-Massade L.

Anticancer Res. 2009 Apr;29(4):1227-31.

21.

Hypoxia down-regulates CCAAT/enhancer binding protein-alpha expression in breast cancer cells.

Seifeddine R, Dreiem A, Blanc E, Fulchignoni-Lataud MC, Le Frère Belda MA, Lecuru F, Mayi TH, Mazure N, Favaudon V, Massaad C, Barouki R, Massaad-Massade L.

Cancer Res. 2008 Apr 1;68(7):2158-65. doi: 10.1158/0008-5472.CAN-07-1190.

22.

Recruitment of the p160 coactivators by the glucocorticoid receptor: dependence on the promoter context and cell type but not hypoxic conditions.

Trousson A, Grenier J, Fonte C, Massaad-Massade L, Schumacher M, Massaad C.

J Steroid Biochem Mol Biol. 2007 May;104(3-5):305-11. Epub 2007 Mar 23.

PMID:
17481888
23.

Hypoxia and estrogen co-operate to regulate gene expression in T-47D human breast cancer cells.

Seifeddine R, Dreiem A, Tomkiewicz C, Fulchignoni-Lataud MC, Brito I, Danan JL, Favaudon V, Barouki R, Massaad-Massade L.

J Steroid Biochem Mol Biol. 2007 May;104(3-5):169-79. Epub 2007 Mar 24.

PMID:
17475478
24.

[Hypoxia, HIF1alpha and estrogen receptor].

Massaad-Massade L.

Bull Cancer. 2004 Sep;91(9):677-83. Review. French.

25.

The functional interaction between HMGA1 and the estrogen receptor requires either the N- or the C-terminal domain of the receptor.

Massaad-Massade L, Tacine R, Dulauroy S, Reeves R, Barouki R.

FEBS Lett. 2004 Feb 13;559(1-3):89-95.

26.

Structure and polymorphisms of human aryl hydrocarbon receptor repressor (AhRR) gene in a French population: relationship with CYP1A1 inducibility and lung cancer.

Cauchi S, Stücker I, Cénée S, Kremers P, Beaune P, Massaad-Massade L.

Pharmacogenetics. 2003 Jun;13(6):339-47.

PMID:
12777964
27.

HMGA1 enhances the transcriptional activity and binding of the estrogen receptor to its responsive element.

Massaad-Massade L, Navarro S, Krummrei U, Reeves R, Beaune P, Barouki R.

Biochemistry. 2002 Feb 26;41(8):2760-8.

PMID:
11851423
28.

Polymorphisms of human aryl hydrocarbon receptor (AhR) gene in a French population: relationship with CYP1A1 inducibility and lung cancer.

Cauchi S, Stücker I, Solas C, Laurent-Puig P, Cénée S, Hémon D, Jacquet M, Kremers P, Beaune P, Massaad-Massade L.

Carcinogenesis. 2001 Nov;22(11):1819-24.

PMID:
11698344
29.

A single d(GpG) cisplatin adduct on the estrogen response element decreases the binding of the estrogen receptor.

Massaad-Massade L, Massaad C, Legendre F, Bas V, Chottard J, Beaune P, Barouki R.

FEBS Lett. 2000 Jan 21;466(1):49-53.

30.
31.

Red blood cell glutathione levels before and during treatment with neoadjuvant chemotherapy cisplatin/5-fluorouracil in patients with head and neck squamous cell carcinoma.

Massaad-Massade L, Domenge C, Rongeat S, Hassoun L, Legros MH, Ropers J, Janot F, Parise O, Gouyette A.

Anticancer Res. 1998 Jan-Feb;18(1A):283-8.

PMID:
9568091
32.

Glutathione system, topoisomerase II level and multidrug resistance phenotype in acute myelogenous leukemia before treatment and at relapse.

Massaad-Massade L, Ribrag V, Marie JP, Faussat AM, Bayle C, Dreyfus F, Gouyette A.

Anticancer Res. 1997 Nov-Dec;17(6D):4647-51.

PMID:
9494583

Supplemental Content

Loading ...
Support Center